Page 15 - 2022_02-Haematologica-web

Editorials
dose L-asparaginase given as a second exposure in a Berlin-Frankfurt- Münster-based treatment: results of the randomized 9102 intermedi- ate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin Oncol. 2001;19(5):1297-1303.
6. Mondelaers V, Suciu S, De Moerloose B, et al. Prolonged versus stan- dard native E. coli asparaginase therapy in childhood acute lym- phoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. Haematologica. 2017;102(10):1727-1738.
7. Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606-615.
8. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95(11):3310-3322.
9. Salzer WL, Burke MJ, Devidas M, et al. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B- lymphoblastic leukemia: a report from the Children's Oncology Group study AALL1131. Cancer. 2018;124(6):1150-1159.
10. Bhatia S, Landier W, Hageman L, et al. 6MP adherence in a multira- cial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2014;124(15):2345-2353.
haematologica | 2022; 107(2)
357